EUVIMEDEUVIMED entdecken
Crossref

Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non–Small-Cell Lung Cancer

Maryam Ebadi, Colton Ladbury, Jason Liu, Adam Rock, Mykola Onyshchenko, Victoria Villaflor, Miguel Villalona-Calero, Ravi Salgia, Erminia Massarelli, Percy Lee, Terence Williams, Arya Amini

Clinical Lung Cancer · 2023-11 · 24 (7) · 651-659

DOI: 10.1016/j.cllc.2023.08.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2023-11. Verfasst von Maryam Ebadi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Washington, Seattle, WA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND PURPOSE: The role of stereotactic body radiation therapy (SBRT) in oligoprogressive non-small-cell lung cancer (NSCLC) is controversial. We evaluated whether SBRT in a subset of patients with oligoprogressive or oligorecurrent NSCLC offers a durable response, obviating the need to change systemic therapy. METHODS: A retrospective analysis of 168 NSCLC patients who underwent SBRT for oligoprogressive or oligorecurrent disease was performed. Oligoprogression was defined as progression in ≤5 lesions during or after systemic therapy following an initial complete or partial response. Oligorecurrence was defined as progression while off systemic therapy. Progression-free survival (PFS), overall survival (OS) and time to next treatment or death (TNT-D) were estimated. RESULTS: Median age was 68 years. Sixty-seven percent of patients were on systemic therapy at the time of progression. Progression at the primary site was present in 31% of the patients. The number of sites of metastatic progression was 0 to 2 in 76% and 3 to 5 in 24% of the patients. Two-year OS and PFS were 56% (95%CI 46%-64%) and 14% (95%CI 8%-21%), respectively. Median TNT-D was 9 months (95%CI 6-11). No grade 4 or 5 toxicity was seen. In multivariable analysis, patients with 3 to 5 sites of metastatic progression had worse OS (HR 2.6, 95%CI 1.5-4.3, P < .001) and shorter TNT-D (HR 1.7, 95%CI 1.1-2.5, P = .01) than those with 0 to 2 sites. CONCLUSION: SBRT is a safe and viable treatment option for oligoprogressive and oligorecurrent NSCLC. Patients with 0 to 2 sites had better OS and longer TNT-D compared to those with 3 to 5 lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsRadiosurgeryHumansAgedRetrospective Studies

Stichwörter der Autor:innen

MetastasisNSCLCOligoprogressionOligorecurrenceSBRT

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Washington, Seattle, WA.
  • Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, CA.
  • Department of Medical Oncology & Therapeutics Research, City of Hope National Cancer Center, Duarte, CA.
  • Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, CA. Electronic address: aamini@coh.org.

Zitieren

APA

Ebadi, M., Ladbury, C., Liu, J., Rock, A., Onyshchenko, M., Villaflor, V., Villalona-Calero, M., Salgia, R., Massarelli, E., Lee, P., Williams, T., & Amini, A. (2023). Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 24(7), 651-659. https://doi.org/10.1016/j.cllc.2023.08.015

Vancouver

Ebadi M, Ladbury C, Liu J, Rock A, Onyshchenko M, Villaflor V, et al. Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 2023;24(7):651-659. doi:10.1016/j.cllc.2023.08.015

BibTeX
@article{Ebadi2023,
  author = {Ebadi, Maryam and Ladbury, Colton and Liu, Jason and Rock, Adam and Onyshchenko, Mykola and Villaflor, Victoria and Villalona-Calero, Miguel and Salgia, Ravi and Massarelli, Erminia and Lee, Percy and Williams, Terence and Amini, Arya},
  title = {Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non–Small-Cell Lung Cancer},
  journal = {Clinical Lung Cancer},
  year = {2023},
  volume = {24},
  number = {7},
  pages = {651--659},
  doi = {10.1016/j.cllc.2023.08.015}
}
Kostenlos starten →